Physician profile
Gregory A Mann
NPI 1154323475
$2,497.13
in general payments reported to CMS, 2019-2025
32 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $209 · 2021: $321 · 2022: $309 · 2023: $406 · 2024: $290 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.92 | 2019-2025 | |
| Pfizer INC. | $218.32 | 2019-2025 | |
| Aspira Women'S Health INC | $158.89 | 2023 | Ova1 |
| Astellas Pharma US INC | $153.46 | 2019-2025 | Veozah, Myrbetriq |
| Biogen, INC. | $149.70 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $145.68 | 2023-2025 | Myfembree |
| Covidien Lp | $138.41 | 2019 | |
| Amgen INC. | $120.14 | 2019 | |
| Mayne Pharma Commercial LLC | $115.29 | 2022-2025 | |
| Boston Scientific Corporation | $102.72 | 2024 | Advantage System |
| Bayer Healthcare Pharmaceuticals INC. | $99.71 | 2019-2023 | |
| Daiichi Sankyo INC. | $78.51 | 2021-2023 | Injectafer |
| Myovant Sciences INC. | $73.56 | 2022 | |
| Merck Sharp & Dohme LLC | $71.76 | 2019-2023 | Gardasil 9 |
| Organon LLC | $53.38 | 2021-2025 | Nexplanon |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $45.90 | 2025 | Myosure Tissue Removal Device, Novasure, Fluent Fluid Management System |
| Avion Pharmaceuticals | $36.57 | 2020-2021 | |
| Ethicon US, LLC | $35.92 | 2019-2022 | |
| Therapeuticsmd, INC. | $35.77 | 2020-2022 | |
| Allergan, INC. | $34.54 | 2019 | |
| Agile Therapeutics, INC. | $30.41 | 2021 | |
| Radius Health, INC. | $29.31 | 2020 | |
| Shield Therapeutics INC | $29.05 | 2022 | |
| Medtronic, INC. | $21.96 | 2025 | Ligasure |
| Duchesnay USA Incorporated | $20.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.46 | 2019 | |
| Roche Diagnostics Corporation | $19.25 | 2019 | |
| Sage Therapeutics, LLC | $17.14 | 2022 | |
| Coopersurgical, INC. | $17.08 | 2021 | |
| Axonics, INC. | $16.78 | 2022 | |
| Gynesonics, INC. | $16.00 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Olympus America INC. | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.